The GLYDER™ Facet Resurfacing System Clinical Study commences European enrollment

According to an announcement by Zyga Technology, Inc., its GLYDER Facet Resurfacing System Clinical Study enrolled and treated the first European patients.

The GLYDER clinical study aims to evaluate the safety and efficacy of the GLYDER device in patients with a history of facet pain. This prospective, multi-center clinical trial will enroll participants based on treatment history and baseline diagnosis.

Pricipal Investigator and Director for the Center of Neurosciences/Chair, Department of Neurosurgery, BG-Clinic Bergmannstrost, Halle, Germany, Professor Hans Jorg Meisel, M.D. Ph.D., said, “The GLYDER device was very easy to implant into the facet joints. Preoperatively, both of these patients had long lasting facet joint syndrome. The first postoperative examinations showed a good result concerning the patients’ lumbar pain giving us the impression of a favorable outcome from the GLYDER surgery. We look forward to continuing the study and reporting the final results.”
Medical Director of the Instituto de Patologia da Coluna, Sao Paulo, Brazil, Luiz Pimenta, M.D., Ph.D, who implanted the first-in-man GLYDER devices said, “Early results suggest that GLYDER could be a good option for treating patients suffering from facet pain. More study of this device is needed so we are looking forward to seeing the results from the European study.”

Nearly 30% patients with low back pain could attribute their suffering to facetogenic pain. Although therapeutic facet injections bring temporary relief to patients suffering from this condition, they require long-term repeat treatments.